EU Regulators Set to Force Illumina's $8bn Cancer Treatment Group Sale
EU regulators are expected to order Illumina, a leading genomics company, to sell its recently acquired cancer treatment group, GRAIL, for around $8 billion due to concerns over competition. The regulators are concerned that Illumina's ownership of GRAIL could hinder competition in the market for liquid biopsy tests, which are used to detect cancer.